



# Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg

Worli, Mumbai – 400 030, India

Tel.: +91 22 6663 5456

Fax: +91 22 6663 5460

Email: auro@aurolabs.com

Web: www.aurolabs.com

Reg. Off / Mfg. Unit:

K-56, M.I.D.C. Tarapur,

Dist. Palghar, Maharashtra – 401506

CIN No. L33125MH1989PLC051910

Date: February 05, 2026

To,  
Listing Department  
BSE Limited  
Pheroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001.

Ref: Security Code No./ISIN: 530233/ INE292C01011

Sub: Outcome of the meeting of Board of Directors dated February 05, 2026.

Dear Sir / Madam,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting to be held on (i.e. Thursday, February 05, 2026), has transacted the following business:

1. Consider and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2025 as recommended by the Audit Committee.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the quarter ended December 31, 2025.
- Limited Review Report received from the Statutory Auditors of the Company.

The Meeting of the Board of Directors commenced at 04:00 p.m. and concluded at 05:00 p.m.

The results along with the QR code will be published in the newspapers in terms of Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

The full format of the financial results shall be available on the website of the Stock exchange where equity shares of the Company are listed i.e. [www.bseindia.com](http://www.bseindia.com) and on Company's website [www.aurolabs.com](http://www.aurolabs.com)

Kindly take the above information on records.

Thanking You,

Yours Faithfully,  
For AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH  
WHOLE TIME DIRECTOR  
DIN: 00230796

Encl.: A/a



# AURO LABORATORIES LIMITED

CIN NO. :- L33126MH1989PLC051910

Regd. Office : K - 56 M.L.D.C INDUSTRIAL AREA, TARAPUR

BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax: +91-22-66635460 Email. [auro@aurolabs.com](mailto:auro@aurolabs.com) Web: [www.aurolabs.com](http://www.aurolabs.com)

## ANNEXURE - I

(Rs. In Lakhs except EPS)

Part - I

Sr. No.	Particulars	Quarter Ended		Nine Months Ended		Year Ended
		31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)
						(Audited)
1	Revenue from Operations	939.30	883.67	305.47	2,090.56	1,185.82
2	Other Income	17.73	97.58	14.09	134.76	67.03
3	Total Income (1 + 2)	957.03	981.25	319.56	2,225.32	1,252.85
4	Expenses					
	a. Cost of raw material consumed	312.00	615.39	118.02	1,052.23	171.42
	b. Purchase of Stock-in-trade	-	1.43	-	1.43	-
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	(199.74)	(419.60)	110.38	(654.10)	233.45
	d. Employee benefits expense	158.83	145.23	3.40	389.75	217.74
	e. Finance Cost	152.25	96.23	24.57	276.55	77.80
	f. Depreciation and amortisation expenses	98.18	65.08	27.00	190.67	81.00
	g. Other Expenses	261.66	305.51	29.37	633.55	316.19
	Total Expenses (4)	783.18	809.26	312.75	1,890.07	1,097.61
5	Profit / (Loss) before exceptional items and tax (3 ± 4)	173.84	171.99	6.81	335.26	155.24
6	Exceptional Items					
7	Profit / (Loss) before tax (5 ± 6)	173.84	171.99	6.81	335.26	155.24
8	Tax expense					
	(a) Current tax expenses for current year	-	-	1.71	-	39.07
	(b) Deferred tax	(21.34)	100.41	-	79.07	-
9	Profit / (Loss) for the period from continuing operation (7 ± 8)	195.18	71.58	5.10	256.18	116.17
10	Profit / (Loss) for discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)	-	-	-	-	-
13	Profit / (Loss) for the period (after tax) (9 ± 12)	195.18	71.58	5.10	256.18	116.17
14	Other Comprehensive Income					
	A. Items that will not be reclassified subsequently to profit or loss					
	(i) Items that will not be reclassified to profit or loss	(15.83)	(44.80)	5.05	(15.83)	5.05
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.60	11.28	(1.27)	0.60	(1.27)
	B. Items that will be reclassified subsequently to profit or loss					
	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income (loss), net of tax (14)	(15.23)	(33.52)	3.78	(15.23)	3.78
15	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)] (13 ± 14)	179.95	38.06	8.88	240.95	119.95
16	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25
17	Other Equity					3,673.56
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares)					
	(a) Basic	3.13	1.15	0.08	4.11	1.86
	(b) Diluted	3.13	1.15	0.08	4.11	1.86
						2.95

### Notes on financial results:-

- The Unaudited Standalone Financial Results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standards (IndAS 34), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (SEBI (LODR) Regulations, 2015) as amended
- The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meeting held on 05th February, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- In accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015, the above Unaudited Standalone Financial Results of the Company are posted on Company's website ([www.aurolabs.com](http://www.aurolabs.com)) and on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) where the Company's shares are listed.
- The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind AS 108 on operating Segments.
- Figures for the previous Period/ Year have been re-grouped/ re-worked/ re-arranged wherever necessary, to make them comparable.
- The Government has notified and brought into force substantial provisions of the Code on Social Security, 2020 ("Social Security Code"); the Occupational Safety, Health and Working Conditions Code, 2020; the Industrial Relations Code, 2020 and the Code on Wages, 2019 (collectively, the "Labour Codes") on 21st, November 2025, which consolidates, subsumes, amends and replaces numerous existing central labour legislations. The Ministry of Labour and Employment had earlier released draft rules for the Code on 13th, November, 2020. Subsequently, on 21st, November, 2025, the Government has notified and brought into force substantial provisions of the Labour Codes. However, certain specific rules and corresponding State-level notifications are yet to be notified. The company is in the process of evaluating the impact of these Labour Codes changes. The company has provided an amount of Rs 3.06 lakhs as provision for gratuity in accordance with Ind AS 19- 'Employee Benefits' and FAQs on key accounting implications arising from the New Labour Codes issued by the Institute of Chartered Accountants of India ('ICAI') in its standalone financial results during the current quarter ended 31st December, 2025.

FOR & BEHALF OF BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED

(SIDDHARTHA DEORAH)  
WHOLE TIME DIRECTOR  
DIN: 00230796

Place : Mumbai  
Dated : 5th February, 2026



**B. L. DASHARDA & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**



**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND NINE MONTHS ENDED  
UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO  
REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS)  
REGULATIONS, 2015**

Review Report to  
The Board of Directors,  
AURO LABORATORIES LTD,  
Mumbai.

- 1) We have reviewed the accompanying Statement of Unaudited Standalone Financial Result of **Auro Laboratories Ltd** ("the Company") for the quarter and nine months ended 31st December, 2025 ("the Statement"), being submitted by Company to the Stock Exchange viz. BSE Limited ("BSE") pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation"), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March, 2019 ("the Circular").
- 2) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting", (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of Entity" ("the Standard"), issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation, read with the circular, including the manner in which it is to be disclosed or that it contains any material misstatement.

**For B.L.Dasharda & Associates**  
**Chartered Accountants**  
**Firm Registration No. :112615W**



**CA Sushant Mehta**  
**Partner**  
**Membership No. :112489**  
Place: Mumbai  
Date : 05<sup>th</sup> February, 2026  
**UDIN No: 26112489JVYUVT8813**